Home Latest Articles
Latest Articles
  • Zhiqiang LI, Huifeng WANG, Yonghong ZHANG, Kun WANG
    World Clinical Drug. 2022, 43(12): 1597-1601.
    Objective

    To investigate the effects of phentolamine combined with fasudil in the treatment of pulmonary heart disease and to analyze the effects of serum growth differentiation factor (GDF)-15 and galectin-3.

    Methods

    A total of 105 patients with pulmonary heart disease who received treatment in the outpatient department of cardiology, general hospital of Taiyuan iron and steel (group) Co., ltd., from June 2019 to June 2021 were selected and divided into observation group (n=53) and control group (n=52) by random number table method. The control group was given phentolamine treatment, and the observation group was given fasudil treatment on the basis of the control group. Clinical efficacy, serum GDF-15, galectin-3, cardiac output (CO), left ventricle ejection fraction (LVEF), 6 minute walking test (6MWT), forced expiratory volume in one second (FVC1), forced vital capacity (FVC), ratio of forced expiratory volume in first second (FEV1) accounted for FVC (FEV1/FVC) and the incidence of adverse reactions were compared in the two groups.

    Results

    After treatment, the total effective rate of the observation group was higher than that of the control group (92.45% vs 67.31%), and the difference was statistically significant (P<0.05). After treatment, the serum levels of GDF-15 and galectin-3 in two groups were decreased compared with before treatment, and the observation group was lower than the control group (P<0.05). The CO, LVEF and 6MWT in two groups were higher than before treatment, and observation group was higher than control group (P<0.05). The levels of FEV1, FVC and FEV1/FVC in the two groups were higher than before treatment, and the observation group was higher than the control group (P<0.05).

    Conclusion

    Phentolamine combined with fasudil is effective in the treatment of patients with pulmonary heart disease, which may be related to the effective improvement of serum GDF-15 and galectin-3 levels.

  • Xiuxia CHEN, Jinling ZHANG, Yanlei WEI
    World Clinical Drug. 2022, 43(12): 1602-1606.
    Objective

    To explore effects of granulocyte colony-stimulating factor (G-CSF) combined with methylprednisolone in the treatment of multiple sclerosis (MS) and its effects on immunoglobulin (Ig), matrix metalloproteinase (MMP)9 and tissue inhibitor of metalloproteinase (TIMP)1.

    Methods

    A total of 127 MS patients treated department of neurology, Dongying district people's hospital from January 2019 to November 2021 were selected and divided into experimental group (n=64) and control group (n=63) by random number table method. The control group was given methylprednisolone treatment, and the experimental group was given G-CSF on the basis of the control group. The clinical efficacy, Ig, MMP9, TIMP1, T lymphocyte subsets, MS multiple sclerosis impact scale (MSIS) score, multidimensional fatigue inventory (MFI) score and the occurrence of adverse reactions were compared between the two groups.

    Results

    After treatment, the total effective rate of experimental group was higher than that of control group (87.50% vs 69.84%), the difference was statistically significant (P<0.05). The levels of IgA, IgG, IgM, MMP9, CD3+, CD4+, CD4+/CD8+, MSIS and MFI score in both groups were decreased over time, and the test group was lower than the control group (P<0.05). The level of TIMP1 was increased with time, and the test group was higher than the control group (P<0.05).

    Conclusion

    In MS patients, G-CSF combined with methylprednisolone has a significant effect, which can effectively improve the levels of Ig, MMP9 and TIMP1, and with good safety.

  • Duo LIU, Yunchu GU, Qingsong HUANG, Weina MA, Fang QIAN
    World Clinical Drug. 2022, 43(12): 1607-1609.
  • Jiahui ZHANG, Chenlin DAI, Xiaoning HE
    World Clinical Drug. 2022, 43(12): 1610-1619.
    Objective

    To evaluate the economic value of denosumab compared with alendronate and zoledronate in the treatment of postmenopausal women with osteoporosis (OP) from the perspective of Chinese health system.

    Methods

    Markov model was established and the treatment period was set to 5 years. The clinical efficacy, health benefits and cost data were obtained from published literatures. Lifetime disease outcomes, effectiveness and costs were calculated under each intervention. With the incremental cost-effectiveness ratio (ICER) as the index, the economy of each intervention was evaluated under the threshold of 3 times GDP per capita. Situation analysis, single factor sensitivity analysis and probability sensitivity analysis were used to test the robustness of the results.

    Results

    The total costs were 19 268, 18 324 and 22 386 yuan in the groups of denosumab, alendronate and zoledronate, respectively. Total quality-adjusted life year (QALY) were 7.58, 7.53 and 7.56. Compared with alendronate, denosumab increased QALY by 0.05, ICER was 18 279 yuan per QALY, which was much lower than 1 times GDP per capita and more economical. Compared with zoledronate, denosumab resulted in an additional 0.03 QALYs and a lower cost, showing absolute advantage. Sensitivity analysis proved the robustness of the results.

    Conclusion

    In the treatment of postmenopausal women with OP, denosumab is more economical than alendronate and has absolute advantages over zoledronate.

  • Ling LEI, Huajuan YAO, Jiayuan QIU, Yan YAO
    World Clinical Drug. 2022, 43(12): 1620-1626.
    Objective

    By analyzing the utilization of monoclonal antibody drugs in sample hospitals in Shanghai in the past three years, the overall development of monoclonal antibody drugs was understood, so as to provide reference for clinical rational drug use.

    Methods

    The clinical sampling data of monoclonal antibody drugs in sample hospitals in Shanghai from 2019 to 2021 were collected from the Hospital Prescription Analysis System database of China National Pharmaceutical Industry Information Center to analyze the clinical application of monoclonal antibody drugs in the past three years.

    Results

    From 2019 to 2021, the number of monoclonal antibody drugs prescriptions and antitumor drugs prescriptions in sample hospitals in Shanghai increased year by year, and the prescription amount fluctuated. The trend of the number of prescriptions and the amount of prescriptions in medical institutions at all levels was basically the same. From 2019 to 2021, trastuzumab, rituximab and bevacizumab had the highest cumulative number of prescriptions and amount of prescriptions. From the market share and year-on-year analysis, it could be seen that the compound growth rate of adalimumab is the fastest, which has reached 1 200%, and pertuzumab is the second fastest, which nearly 700%, meanwhile, the market share is also relatively high, nearly 15%. In 2021, the treatment of monoclonal antibody drugs in sample hospitals in Shanghai mainly focused on anti-tumor therapy. The indications with more prescriptions of monoclonal antibody drugs for tumor treatment were breast cancer, intestinal cancer and lymphoma, respectively. The drugs with the largest number of prescriptions were trastuzumab, pertuzumab, bevacizumab, rituximab and cetuximab.

    Conclusions

    Monoclonal antibody drugs has been widely used in clinical practice, and the use of monoclonal antitumor drugs is occupy a dominant position.

  • Yujia GONG, Yufan WANG
    World Clinical Drug. 2022, 43(12): 1627-1632.

    Gestational diabetes mellitus (GDM) is one of the common complications during pregnancy, conferring an increased risk of long-term abnormal glucose metabolism and cardiovascular disease for both mother and children. Due to socioeconomic factors, patients' health awareness and family-related practicalities, less than 50% of women with GDM partake in postpartum glucose testing. Based on the existing research evidence, this paper summarized some strategies and suggestions for standardized postpartum management of GDM and improvement of follow-up rate, aiming to improve the public and medical staffs' awareness of standardized postpartum management of GDM and the level of hospital management.

  • Yanan YU, Qi SONG, Jun LIU, Kun MA, Zhong WANG
    World Clinical Drug. 2022, 43(12): 1633-1636.

    Treatment of different diseases with same method is one of the characteristics and essence of traditional Chinese medicine (TCM). How to use scientific methods and objective data to verify the effect of syndrome differentiation and treatment of different diseases with same method, and to provide high-quality clinical evidence, is the current hot spot and difficulty in the field of TCM clinical research. This paper combined innovative clinical basket design method and decision model, and took the clinical research model of treatment of different gynecological diseases with same method of TCM as the entry point, so as to provide some suggestions and thoughts on how to better reflect the theory of treatment of different diseases with same method in precision medicine, and establish the clinical research model of treatment of different diseases with same method of TCM "combination of syndrome and disease".

  • Yijun ZHAO, Tiezheng LOU, Yuehui DONG, Can CUI, Heng WANG, Zhenyi WANG
    World Clinical Drug. 2022, 43(12): 1637-1640.

    Ulcerative colitis (UC) is a chronic nonspecific inflammatory disease of the colorectal, and its pathogenesis has not been fully defined. Hypoxia-inducible factor (HIIF)-1α is directly or indirectly involved in the pathogenesis of UC, causing intestinal flora imbalance, resulting in the increase of enterogenic and conditioned pathogens, and the destruction of intestinal mucosal barrier structure, resulting in increased vascular permeability. Intestinal bacteria and bacterial products migrate to mucosal laminae propria, causing activation of immune cells and infiltration of inflammatory cells, thus increasing the level of serum pro-angiogenesis factors and imbalance of the effect of angiogenesis inhibitors, leading to pathological angiogenesis, thus inducing the progression of UC. This paper mainly summarized the mechanism of HIF-1α in the UC process, and provides innovative ideas for the treatment of ulcerative colitis by this factor and drug development.

  • Yujie SUN, Fenghua GU
    World Clinical Drug. 2022, 43(12): 1641-1644.

    Chronic obstructive pulmonary disease (COPD) is a common preventable and treatable disease characterized by persistent respiratory symptoms and airflow restriction, caused by airway and/or alveolar abnormalities resulting from significant exposure to harmful particulate matter or gases. Difficulty breathing, cough and/or phlegm are the most common symptoms of COPD. The incidence and mortality of COPD are increasing year by year and is the fourth leading cause of death worldwide. Reactive oxygen species produced by cigarette smoke can damage lung structure and function, causing pulmonary oxidative stress disorder and COPD. Oxidative stress is the key to the pathogenesis of COPD. Traditional COPD drugs have limited ability to control oxidative stress, and clinical evidence of antioxidant stress is insufficient. Thioredoxin and N-acetyl-L-cysteine as molecules of the body's own antioxidant defense system have become research hotspots. This paper reviewed the pathogenesis of oxidative stress and research hotspot of antioxidants of COPD to provide reference for clinical practice.

  • Xiu WANG, Xuefang YAO, Jinxi DING
    World Clinical Drug. 2022, 43(11): 1387-1392.

    China has initially established early resolution mechanism of patent disputes (ERMPD) for biologics, but it is not yet complete. On the basis of clarifying the definition, function, type of the mechanism and content of typical national mechanism, this paper discusses the influencing factors of mode selection, so as to provide references for China to improve the ERMPD for biologics in the future. The present complete ERMPD for biologics can be divided into “soft linkage mode” and “hard linkage mode”. The model selection affected by factors such as mode function, industrial development, patent protection features, and international trade strategy. It is suggested that when improving the ERMPD for biologics in the future, China should combine the above factors and choose an institutional model that is more suitable for its national conditions.

News